The SONIA trial shows the power and challenges of academic research

IF 81.1 1区医学 Q1 ONCOLOGY

Nature Reviews Clinical Oncology Pub Date : 2025-02-24 DOI:10.1038/s41571-025-01004-2

Shani Paluch-Shimon, Fatima Cardoso

引用次数: 0

Abstract

The thought-provoking SONIA trial showed that patients with hormone receptor-positive, HER2-negative advanced-stage breast cancer receiving deferred (second-line) versus first-line cyclin dependent-kinase (CDK) 4/6 inhibitors have noninferior progression-free survival after second-line treatment; such an approach also results in substantial cost savings. Herein, we discuss some important limitations of this trial and argue that, owing to their effect on overall survival, CDK4/6 inhibitors should remain the standard-of-care first-line therapy.

查看原文本刊更多论文

索尼娅试验显示了学术研究的力量和挑战

发人深省的SONIA试验显示，激素受体阳性，her2阴性的晚期乳腺癌患者接受延迟（二线）与一线细胞周期蛋白依赖性激酶（CDK） 4/6抑制剂的二线治疗后无进展生存期不佳；这种方法还可以节省大量的成本。在此，我们讨论了该试验的一些重要局限性，并认为，由于它们对总生存期的影响，CDK4/6抑制剂仍应作为标准护理一线治疗。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Nature Reviews Clinical Oncology 医学-肿瘤学

CiteScore

99.40

自引率

0.40%

发文量

114

审稿时长

6-12 weeks

期刊介绍： Nature Reviews publishes clinical content authored by internationally renowned clinical academics and researchers, catering to readers in the medical sciences at postgraduate levels and beyond. Although targeted at practicing doctors, researchers, and academics within specific specialties, the aim is to ensure accessibility for readers across various medical disciplines. The journal features in-depth Reviews offering authoritative and current information, contextualizing topics within the history and development of a field. Perspectives, News & Views articles, and the Research Highlights section provide topical discussions, opinions, and filtered primary research from diverse medical journals.